Claims for Patent: 11,851,437

Summary for Patent: 11,851,437

Title:	Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Abstract:	The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Inventor(s):	Zhiwei Wang, Yunhang Guo, Gongyin Shi
Assignee:	BeiGene Switzerland GmbH
Application Number:	US17/901,951
Patent Claims:	1. Crystalline Form A of Compound 1, made by crystallizing the crystalline Form A of Compound 1 from an amorphous form of Compound 1, wherein the crystalline Form A is characterized by an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°. 2. The crystalline Form A of claim 1, wherein the crystalline Form A has an enantiomeric excess value of at least 45%. 3. The crystalline Form A of claim 1, wherein the crystalline Form A has a purity of at least 99.5%. 4. The crystalline Form A of claim 1, wherein the crystalline Form A does not change its crystal form after being stored at about 80° C. for 2 days. 5. The crystalline Form A of claim 1, wherein the crystalline Form A does not change its crystal form after being stored at about 25° C. under 60% relative humidity for up to 24 months. 6. The crystalline Form A of claim 1, wherein the crystalline Form A does not change its crystal form after being stored at about 40° C. under 75% relative humidity for up to 6 months. 7. A pharmaceutical composition comprising the crystalline Form A of claim 1 and a pharmaceutically acceptable excipient. 8. A composition comprising the crystalline Form A of claim 1 and an amorphous form of Compound 1. 9. The composition of claim 8, wherein the amorphous form has: (i) a mid-point temperature of a glass transition temperature of about 79.7° C.; and/or (ii) an enantiomeric excess value of at least 97%. 10. The Crystalline Form A of claim 1, wherein the crystalline Form A is further characterized by an X-ray powder diffraction peak selected from 12.2±0.2°, 12.9±0.2°, and 15.6±0.2°. 11. Crystalline Form A of Compound 1, wherein: (i) the crystalline Form A is characterized by an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°; and (ii) the crystalline Form A (a) does not change its crystal form after being stored at about 80° C. for 2 days; (b) does not change its crystal form after being stored at about 25° C. under 60% relative humidity for up to 24 months; or (c) does not change its crystal form after being stored at about 40° C. under 75% relative humidity for up to 6 months. 12. The crystalline Form A of claim 11, wherein the crystalline Form A has a melting point onset temperature of 139±2° C. 13. The crystalline Form A of claim 11, wherein the crystalline Form A has an enantiomeric excess value of at least 45%. 14. The crystalline Form A of claim 11, wherein: the crystalline Form A does not change its crystal form after being stored at about 80° C. for 2 days; the crystalline Form A does not change its crystal form after being stored at about 25° C. under 60% relative humidity for up to 24 months; and the crystalline Form A does not change its crystal form after being stored at about 40° C. under 75% relative humidity for up to 6 months. 15. The crystalline Form A of claim 11, wherein the crystalline Form A has a purity of at least 99.5%. 16. A pharmaceutical composition comprising the crystalline Form A of claim 12 and a pharmaceutically acceptable excipient. 17. A composition comprising the crystalline Form A of claim 11 and an amorphous form of Compound 1. 18. The composition of claim 17, wherein the amorphous form has: (i) a mid-point temperature of a glass transition temperature of about 79.7° C.; and/or (ii) an enantiomeric excess value of at least 97%. 19. The Crystalline Form A of claim 11, wherein the crystalline Form A is further characterized by an X-ray powder diffraction peak selected from 12.2±0.2°, 12.9±0.2°, and 15.6±0.2°. 20. A composition comprising: Crystalline Form A form of Compound 1, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°; and an amorphous form of Compound 1. 21. The composition of claim 20, wherein the crystalline Form A has a melting point onset temperature of 139±2° C. 22. The composition of claim 20, wherein the crystalline Form A has an enantiomeric excess value of at least 45%. 23. The composition of claim 20, wherein the crystalline Form A has a purity of at least 99.5%. 24. The composition of claim 20, wherein the crystalline Form A does not change its crystal form after being stored at about 80° C. for 2 days. 25. The composition of claim 20, wherein the crystalline Form A does not change its crystal form after being stored at about 25° C. under 60% relative humidity for up to 24 months. 26. The composition of claim 20, wherein the crystalline Form A does not change its crystal form after being stored at about 40° C. under 75% relative humidity for up to 6 months. 27. The composition of claim 20, wherein the amorphous form has a mid-point temperature of a glass transition temperature of about 79.7° C. 28. A pharmaceutical composition comprising the composition of claim 20 and a pharmaceutically acceptable excipient. 29. The composition of claim 20, wherein the crystalline Form A is further characterized by an X-ray powder diffraction peak selected from 12.2±0.2°, 12.9±0.2°, and 15.6±0.2°.